Pembrolizumab versus Ipilimumab in Advanced Melanoma
The anti-PD-1 antibody pembrolizumab prolonged progression-free survival and overall survival and had less high-grade toxicity than did ipilimumab in patients with advanced mela...
Publications
1 shownFrequent Co-Authors
Researcher Info
- h-index
- 1
- Publications
- 1
- Citations
- 5,661
- Institution
- Merck & Co., Inc., Rahway, NJ, USA (United States)
External Links
Identifiers
- ORCID
- 0000-0002-3328-6792
Impact Metrics
h-index
1
h-index: Number of publications with at least h citations each.